Townsend & Associates Inc Raises Stock Position in Pfizer Inc. (NYSE:PFE)

Townsend & Associates Inc boosted its holdings in Pfizer Inc. (NYSE:PFE) by 26.1% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 59,300 shares of the biopharmaceutical company’s stock after buying an additional 12,257 shares during the period. Pfizer accounts for approximately 2.0% of Townsend & Associates Inc’s holdings, making the stock its 11th biggest position. Townsend & Associates Inc’s holdings in Pfizer were worth $2,101,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. Country Trust Bank grew its position in shares of Pfizer by 1.0% during the third quarter. Country Trust Bank now owns 472,120 shares of the biopharmaceutical company’s stock valued at $16,963,000 after purchasing an additional 4,446 shares in the last quarter. Accurate Investment Solutions Inc. grew its position in shares of Pfizer by 82.3% during the third quarter. Accurate Investment Solutions Inc. now owns 189,788 shares of the biopharmaceutical company’s stock valued at $6,819,000 after purchasing an additional 85,685 shares in the last quarter. Pacer Advisors Inc. grew its position in shares of Pfizer by 13.8% during the third quarter. Pacer Advisors Inc. now owns 606,501 shares of the biopharmaceutical company’s stock valued at $21,792,000 after purchasing an additional 73,592 shares in the last quarter. Quattro Financial Advisors LLC purchased a new position in shares of Pfizer during the third quarter valued at about $373,000. Finally, We Are One Seven LLC grew its position in shares of Pfizer by 3.0% during the third quarter. We Are One Seven LLC now owns 50,756 shares of the biopharmaceutical company’s stock valued at $1,824,000 after purchasing an additional 1,498 shares in the last quarter. Institutional investors and hedge funds own 71.69% of the company’s stock.

Shares of NYSE:PFE traded up $0.62 during trading on Friday, reaching $36.41. The company’s stock had a trading volume of 3,654,971 shares, compared to its average volume of 19,407,336. The company has a current ratio of 1.47, a quick ratio of 1.21 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 12 month low of $33.97 and a 12 month high of $46.47. The firm’s 50 day simple moving average is $35.94 and its two-hundred day simple moving average is $39.97. The stock has a market capitalization of $195.97 billion, a PE ratio of 12.14, a price-to-earnings-growth ratio of 2.82 and a beta of 0.66.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 EPS for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm had revenue of $13.26 billion during the quarter, compared to the consensus estimate of $13.43 billion. During the same quarter last year, the firm earned $0.77 EPS. The firm’s revenue for the quarter was down 1.5% compared to the same quarter last year. Research analysts anticipate that Pfizer Inc. will post 2.81 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a $0.36 dividend. This represents a $1.44 annualized dividend and a yield of 3.95%. The ex-dividend date of this dividend is Thursday, November 7th. Pfizer’s payout ratio is currently 48.00%.

A number of brokerages have recently weighed in on PFE. JPMorgan Chase & Co. raised their price objective on Pfizer from $37.00 to $46.00 and gave the company a “neutral” rating in a research report on Thursday, September 19th. They noted that the move was a valuation call. ValuEngine upgraded Pfizer from a “sell” rating to a “hold” rating in a research report on Wednesday, October 2nd. Bank of America lowered Pfizer from a “buy” rating to a “neutral” rating in a research report on Tuesday, July 30th. DZ Bank raised shares of Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price target for the company in a report on Wednesday, August 28th. Finally, UBS Group reaffirmed a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a report on Monday, August 5th. Twelve equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has assigned a strong buy rating to the company. The stock has an average rating of “Hold” and a consensus price target of $45.20.

In other news, major shareholder Pfizer Inc acquired 50,000 shares of the firm’s stock in a transaction on Tuesday, September 17th. The stock was acquired at an average price of $18.00 per share, with a total value of $900,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Scott Gottlieb acquired 3,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The stock was purchased at an average cost of $34.72 per share, with a total value of $104,160.00. Following the purchase, the director now owns 3,000 shares of the company’s stock, valued at $104,160. The disclosure for this purchase can be found here. 0.09% of the stock is owned by company insiders.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Read More: What is a trade deficit?

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit